Related Experiment Videos
Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives
R Moss Hampton1, Huabin F Zhang, Christopher Barnowski
1Texas Tech University School of Medicine, Odessa, TX 79763, USA. moss.hampton@ttuhsc.edu
Background:
This retrospective analysis evaluated the association of age and weight with cycle control in women using either of two formulations of low-estrogen-dose oral contraceptives.
Study Design:
Data for this secondary analysis were derived from a randomized multicenter trial assessing the efficacy and safety of norgestimate (NGM) 180/215/250 mcg/ethinyl estradiol (EE) 25 mcg (n=1506) and norethindrone acetate 1 mg/EE 20 mcg (n=1057). In this retrospective analysis, the incidence of breakthrough bleeding/spotting (BTB/S) was evaluated in women stratified by age (18-24, 25-34 and >34 years) and weight (
Results:
A lower percentage of women experienced BTB/S with NGM/EE during most cycles, regardless of age or weight, compared with norethindrone acetate/EE. At Cycle 6, the incidences of BTB/S for NGM/EE versus norethindrone acetate/EE were as follows: 18-24 years, 10.9% versus 29.7% (p<.0001); 25-34 years, 10.9% versus 18.6% (p<.001); >34 years, 8.1% versus 19.1% (p<.005);
Conclusion:
NGM/EE provided better cycle control as defined by BTB/S compared with norethindrone acetate/EE, regardless of subject age or weight for six cycles.
Related Concept Videos
Intrauterine Drug Delivery Systems
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Birth Control Methods
Dosage Regimen: Multiple Oral Dosage
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Ovarian Cycle